- $56.53m
- $21.60m
- $21.74m
- 66
- 46
- 69
- 63
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.32 | ||
| Price to Tang. Book | 0.44 | ||
| Price to Free Cashflow | 28.21 | ||
| Price to Sales | 2.22 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -23.08% | ||
| Return on Equity | -21.86% | ||
| Operating Margin | -169.38% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 9.23 | 65.18 | 12.53 | 13.16 | 21.74 | 32.6 | 75.4 | 23.88% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Prenetics Global Ltd is a company principally engaged in the provision of diagnostic and preventive products and services. The Company operates its business through two segments. The Diagnostics segment is mainly engaged in the sale of precision oncology testing services. The Prevention segment is mainly engaged in the design and sale of genetics testing, including update services, and stool-based deoxyribonucleic acid (DNA) tests for early colorectal cancer screening. The Company's products and services include CircleDNA, ACTOnco, ACTHRD and other products. The in-house developed consumer genetic testing product, CircleDNA, offers comprehensive DNA tests capitalizing on in-house developed testing algorithm. ACTOnco is a comprehensive cancer test used to guide treatment selection for major solid tumors. ACTHRD is a test for the homologous recombination deficiency status of cancer patients. The Company is also engaged in consumer health products by a new health and wellness brand IM8.
Directors
- Last Annual
- December 31st, 2023
- Last Interim
- September 30th, 2024
- Incorporated
- January 1st, 1970
- Public Since
- July 6th, 2021
- No. of Employees
- 320
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Global Market- Shares in Issue
- 11,453,009
- Address
- Unit 701-706, K11 Atelier King's Road,
- Web
- https://ir.prenetics.com/
- Phone
- +852 null22109588
- Auditors
- KPMG
Upcoming Events for PRE
Similar to PRE
89bio
NASDAQ Global Market
Abivax SA
NASDAQ Global Market
ABPRO Holdings
NASDAQ Global Market
AC Immune SA
NASDAQ Global Market
Acrivon Therapeutics
NASDAQ Global Market
FAQ
As of Today at 22:44 UTC, shares in Prenetics Global are trading at $5.31. This share price information is delayed by 15 minutes.
Shares in Prenetics Global last closed at $5.31 and the price had moved by -0.28% over the past 365 days. In terms of relative price strength the Prenetics Global share price has underperformed the S&P500 Index by -10.08% over the past year.
The overall consensus recommendation for Prenetics Global is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out morePrenetics Global does not currently pay a dividend.
Prenetics Global does not currently pay a dividend.
Prenetics Global does not currently pay a dividend.
To buy shares in Prenetics Global you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $5.31, shares in Prenetics Global had a market capitalisation of $56.53m.
Here are the trading details for Prenetics Global:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: PRE
Based on an overall assessment of its quality, value and momentum Prenetics Global is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Prenetics Global is $9.00. That is 69.34% above the last closing price of $5.31.
Analysts covering Prenetics Global currently have a consensus Earnings Per Share (EPS) forecast of -$3.30 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Prenetics Global. Over the past six months, its share price has outperformed the S&P500 Index by +15.57%.
As of the last closing price of $5.31, shares in Prenetics Global were trading +7.8% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Prenetics Global PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $5.31.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Prenetics Global's directors